Home > Pulmonology > ATS 2019 > Pulmonary Vascular Disease and Interstitial Lung Disease > Pulmonary Arterial Hypertension: Early Treatment with Selexipag Most Effective

Pulmonary Arterial Hypertension: Early Treatment with Selexipag Most Effective

Presented By
Prof. Sean Gaine, Mater Misericordiae University Hospital, Ireland
Conference
ATS 2019
Trial
GRIPHON

New post-hoc analyses from the large-scale GRIPHON trial assessing selexipag in patients with pulmonary arterial hypertension (PAH) demonstrate that early, aggressive treatment after diagnosis is associated with the greatest benefits, irrespective of background therapy [1].

Around a third of PAH patients currently die within 5 years of diagnosis; early recognition and prompt treatment of the disease are key to achieving sustained long-term benefits [2]. The GRIPHON study evaluated the long-term efficacy and safety of oral selexipag in 1,156 patients with PAH across 181 centres from 39 countries. It is the largest randomised, controlled, outcome trial ever conducted in patients with PAH and generated data that is still being analysed. A 40% reduction in the primary composite endpoint of morbidity/mortality was met (i.e. disease progression, worsening of PAH resulting in hospitalisation, initiatio...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on